Categories: News

Modular Medical Announces Addition to the Russell Microcap(R) Index

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) (“Modular Medical”), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Modular Medical

Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.”

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

All trademarks mentioned herein are the property of their respective owners.

CONTACT:

Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com

SOURCE: Modular Medical, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

ZEISS and LG Chem join forces to strengthen the photopolymer supply chain for advanced optics

ZEISS and LG Chem established a strategic framework for industrial-scale photopolymer film supply in advanced…

5 hours ago

Quantum BioPharma Ltd. Announces Corporate Updates

Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)…

8 hours ago

Dräger achieves perfect-score CMMC Level 2 Certification reinforcing cybersecurity leadership in Defense and Government healthcare and safety technology

Certification ensures the highest level of data security for mission-critical medical and safety technology TELFORD,…

11 hours ago

Waystar Reports Third Quarter 2025 Results

Q3 revenue growth of 12% year-over-year Q3 net income of $30.6 million and non-GAAP net…

11 hours ago

PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth

PatientNow, the leader in practice management and growth technology for aesthetics practices, today announced the…

11 hours ago